Pfizer Inc. said on January 21 the U.S. health regulator declined to approve somatrogon as a treatment for growth hormone deficiency in children that the company developed with partner Opko Health Inc.

The World Health Organization on January 21 recommended extending the use of a reduced dosage of Pfizer’s COVID-19 vaccine to children aged 5 to 11 years old.

A small preliminary laboratory study has shown that levels of Omicron-neutralizing antibodies of people vaccinated with Russia’s Sputnik V vaccine did not decline as much as those who had Pfizer shots.

Pfizer released data from several studies showing that nirmatrelvir, the active main protease inhibitor of the company’s antiviral combination therapy Paxlovid (nirmatrelvir/ritonavir), is effective against the Omicron variant of SARS-CoV-2. Additionally, a study conducted by 23andMe and published in Nature Genetics identified a genetic risk factor tied to the loss of smell from COVID-19.

Speaking with French newspaper Le Figaro, Pfizer Chief Executive Officer Albert Bourla said he believes the world will “return to normal life” sometime during the spring of 2022.

The U.S. Food and Drug Administration approved drugs from AbbVie Inc. and Pfizer Inc. for treating the skin disease eczema, the companies said on Jan. 14.

Sparked by more than two years of virtual meetings due to the COVID-19 pandemic, Pfizer is cutting the company’s sales staff as more and more physicians’ offices and healthcare facilities prefer fewer face-to-face interactions with vendors. That preference for a virtual experience is expected to remain even after the pandemic wanes.

Pfizer Inc. said on Wednesday booster doses of the company’s COVID-19 vaccine can be administered along with its pneumonia vaccine and produced strong safety and immune responses in people aged 65 and above in a late-stage study.

California-based Dren Bio and Pfizer partnered on a deal valued at more than $1 billion to discover and develop therapeutic bispecific antibodies for select oncology targets.

The 2022 virtual J.P. Morgan Healthcare Conference got off to a roaring start with deal announcements and plans to drive biopharma companies through the year.